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Background: We designed the PROXIMA study (Patient-Reported Outcomes and Xolair® In the Management of
Asthma) to determine the proportion of patients with severe asthma sensitive to perennial allergens, and to
evaluate asthma control and treatment adherence up to 12 months in patients treated with omalizumab in Italian
population. In addition, an ancillary study was designed to explore protein biomarkers and characterize them in
relation to severe allergic asthma and treatment effects by proteomic approach.
Methods: PROXIMA is an observational, multicenter, cross-sectional and prospective cohort study conducted at 25
centers in Italy, in outpatient settings. The study consists of two phases: 1) a cross-sectional phase plans to enroll
600 patients with severe allergic asthma, in step 4 therapy as per GINA guidelines, aged ≥18 years, needing a step
up in therapy, and 2) a longitudinal phase on patients who will start omalizumab add-on therapy per clinician’s
judgment at baseline visit (approximately 180–240 patients). The primary variable of the cross-sectional phase is the
proportion of patients with severe asthma presenting with perennial form of allergy (skin prick test or in vitro test).
The primary variable of longitudinal phase is proportion of patients who achieve disease control (assessed by
Asthma Control Questionnaire [ACQ]) with omalizumab at 6 months, and maintain it at 12 months. Secondary
variables are patient compliance to omalizumab, patient-reported perception of cognitive and emotional impact
of the illness, assessed by Brief Illness Perception Questionnaire (Brief IPQ) and the health related quality of life
evaluated by the EuroQoL 5D-3 L (EQ-5D-3 L). Safety endpoints will be recorded during the course of the study.
Patients participating in the longitudinal phase will be enrolled for ancillary study if they provide additional informed
consent. Protein species in complex mixtures will be identified using innovative MudPIT (Multidimensional Protein
Identification Technology) method.
Conclusions: The results of this observational study will provide estimate of patient population allergic to perennial
allergens in Italy and information on patient-reported outcomes with omalizumab therapy in a real-world setting.
The exploratory proteomic analysis on asthma biomarkers could eventually provide new data to identify responder
patients to anti IgE therapy.
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Asthma is a highly prevalent respiratory disorder
characterized by chronic inflammation and hyper-
responsiveness of airways, and variable airflow ob-
struction, often reversible [1]. More than 300 million
people are affected by asthma, worldwide [1,2]. Of this
population, about 10% is estimated to have severe asthma
accounting for significant burden of morbidity and mor-
tality [3,4]. In Italian population (GEIRD Study), the
median prevalence of asthma was reported to be 6.6%,
ranging from 4.5%–8.5%, recording a 35% increase in the
last 2 decades [5]. Clinically, many different forms or
phenotypes of asthma have been recognized; however,
allergic asthma affects a substantial proportion of pa-
tients with asthma [2]. Atopy and allergic mechanisms
have been implicated for asthma in 50-80% of the pa-
tients and in approximately 50% of patients with severe
asthma [6-8]. In Italy, allergic asthma affects >60% pa-
tients with asthma [5].
In patients with allergic asthma, who are already sensi-
tized to a specific environmental allergen, exposure to
same allergen acts as powerful trigger for asthmatic re-
sponse, which is mast-cell driven in the early phase and
inflammatory-cell driven in late phase [1,8]. Markedly
increased levels of IgE antibodies are found in individ-
uals with allergic asthma. IgE antibodies cause chronic
airway inflammation via high-affinity (FcεRI) or low-
affinity (FcεRII) IgE receptors present on effector cells
such as mast cells, and basophils [1,8]. Antigen induced
cross-bridging of IgE-FcεRI cell surface complexes,
triggering degranulation of effector cells, gives rise to
various symptoms of allergy. The distinction between
perennial and seasonal allergic asthma are often made
on the basis of the seasonality of sensitizing allergens
(seasonal and perennial) and the detection IgE specific
to allergen [8]. However, distinction between seasonal
and perennial allergic asthma based on seasonality of al-
lergens has been a topic for discussion among clinicians
because of certain overlapping characteristics of aller-
gens. Recently, it was proposed to replace the terms
seasonal and perennial with the ‘intermittent’ and
‘persistent’ - disease or -exposure to allergens. The con-
cept was intended to introduce change in the treatment
approach for allergic diseases taking into account the
overlap between the treatment of seasonal and perennial
allergies. The new definition was proposed because the
concept of seasonality could not be applied to some
of the perennial allergens (occupational, mite and pet
allergens) and some seasonal environmental allergens
(pollen) might be considered as perennial owing changes
in climate. Moreover, the majority of patients are usually
sensitized with multiple allergens (polysensitization) with
occupational allergens, mite and pet allergens, and pres-
ence of cross-reactivity and pan-allergens [9].Omalizumab, a recombinant monoclonal antibody
(IgE antibody), reduces free IgE levels by binding to the
Fc domain of the circulating IgE and thereby inhibiting
IgE binding to FcεRI receptors. In addition omalizumab
also blocks the IgE-dependent uptake of allergens by
mature myeloid dendritic cells, thereby affecting the
chronic allergic response [7,10]. Currently, omalizumab
is the recommended treatment of severe allergic asthma
in patients not responding to Step 4 of the GINA treat-
ment approach, and need therapeutic step up to Step 5
[11]. In the European Union, omalizumab is approved
as add-on therapy in adults, adolescents, and children
(6 to <12 years of age) with severe persistent allergic
asthma inadequately-controlled (reduced lung function,
frequent daytime symptoms or night-time awakenings,
and multiple documented severe asthma exacerbations),
despite daily high-dose inhaled corticosteroids (ICS), plus
a long-acting inhaled beta2-agonist (LABA) [12].
Medical literature lacks information on the proportion
of patients with severe asthma presenting with the per-
ennial form of allergy in Italy. Moreover, data on the
effectiveness of omalizumab as add-on therapy for pa-
tients with severe persistent allergic asthma in the Italian
population is limited.
Primary objectives
The PROXIMA (Patient Reported Outcomes and Xolair®
In the Management of Asthma) study was designed to
estimate the prevalence of perennial allergy in adult pa-
tients with severe allergic asthma in the Italian popula-
tion and to evaluate the proportion of patients in this
demographics who achieve disease control at 6 months
and maintain it at 12 months in a sample of patients
treated with omalizumab.
Methods
Study design and patient population
PROXIMA is an observational, multicenter, cross-
sectional and prospective cohort study conducted at
25 centers in Italy, in outpatient settings (Hospitals
and University centers specialized in the treatment of
asthma). The study comprises of 2 phases, a cross-
sectional and a longitudinal phase (12 months). Patients
entered in the longitudinal phase will be treated with
omalizumab as per “scheda tecnica” [12] (Figure 1).
In the cross-sectional phase, about 600 patients
aged ≥18 years, diagnosed with severe allergic asthma
currently in Step 4 (as defined by GINA international
guidelines) and need a step up in therapy will be enrolled.
About 30%–40% (180–240 patients with perennial allergic
asthma) are estimated to enter the longitudinal phase,
start therapy with omalizumab, followed up for 12 months.
Omalizumab as treatment choice will be based on clini-
cian’s judgment and local treatment guidelines. As the
Figure 1 Study design and assessments.
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unable to complete the patient questionnaires will not be
enrolled for the study. Patients participating in the longi-
tudinal phase will have the option to participate to an
ancillary study (The PROXIMA sub-study: exploratory
proteomic analysis on asthma biomarkers).
This study was designed and shall be implemented
and reported in accordance with the Guidelines for
Good Pharmacoepidemiology Practices (GPP) of the
International Society for Pharmacoepidemiology (ISPE
2008), the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) guidelines,
the ethical principles laid down in the Declaration of
Helsinki, and the AIFA (Agenzia Italiana del Farmaco)
guideline for the classification and management of
observational studies on drugs [13-15].
Eligible patients may be enrolled only after written
informed consent. The study documents including
protocol and informed consent forms were approved by
the ethics committees and institutional review boards of
all participating centers.
Variables
The two primary variables of the study are the propor-
tion of patients with severe allergic asthma having
allergy to a perennial form of aeroallergens (at baseline
cross-sectional phase) and the proportion of patients
with asthma control at Months 6 and 12 (in longitudinal
phase) with omalizumab therapy. Secondary variables in
the cross-sectional phase are the level of asthma control,
patient disease perception at baseline in all patients(whole sample) and in patients with perennial allergy
compared with seasonal allergy, quality of life and
healthcare resource utilization. In the longitudinal phase
secondary variables are, 1) proportion of patients with
at least 1 episode of asthma exacerbation during the
12 months study period; 2) patient compliance to omali-
zumab at 6 and 12 months; 3) persistence with omalizu-
mab treatment for 12 month; and 4) quality of life and
healthcare resource utilization at months 6 and 12.
Assessments
Patients with perennial form of allergy will be identified
by clinicians on the basis of the results of skin prick test
or in vitro tests for the reactivity to a perennial aeroaller-
gen. Asthma disease control will be assessed by the
Asthma Control Questionnaire (ACQ) using a 7-point
scale, where 0 indicates well-controlled and 6 signify
extremely poorly controlled asthma [16]. A patient will
be defined (as per protocol) as controlled if the ACQ
total score will be between 0 and 4.
Brief Illness Perception Questionnaire (Brief IPQ) and
EuroQoL 5D-3 L (EQ-5D-3 L) scale will be used to
assess patient disease perception and quality of life, re-
spectively. Brief IPQ is a 9-item questionnaire designed
to rapidly assess cognitive and emotional representations
of illness [17]. All of the questionnaire items (except the
causal question, item 9) are rated using a 0 to-10 re-
sponse scale; five of the items assess cognitive illness
representations, two of the items assess emotional repre-
sentations and one item assesses illness comprehensibil-
ity. Assessment of the causal representation is by an
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most important causal factors in their illness. EQ-5D-
3 L scale consists of two sections, EQ-5D-descriptive
system and the EQ-visual analogue scale (EQ-VAS)
[18,19]. The EQ-5D-3 L descriptive system assesses 5
dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension
has 3 levels: no problems, some problems, extreme
problems. EQ-VAS is used as a quantitative measure
of health as judged by the individual respondents on
a visual analogue scale from 0 to 100, where 0 the
“worst imaginable health state” and 100 is the “best
imaginable health state”.
Patient compliance will be assessed as the ratio be-
tween the number of injections of omalizumab adminis-
tered during the observational period (month 6 and 12)
over the total number of planned injections. Omalizumab
persistence during the 12 months will be assessed by
Kaplan-Meier survival curve analysis, where the event of
interest will be the treatment discontinuation.
The consumption of healthcare resources will be
assessed by using a dedicated questionnaire collecting
information on the number of hospitalizations, number
of emergency department visits, number of outpatient
visits and number of laboratory and diagnostic tests.
Asthma exacerbations, serum IgE levels and forced
expiratory volume in 1 s (FEV1) percent (at baseline) will
be measured by using standard clinical and laboratory
assessment methods [20]. Safety assessments consist of
clinical examination, monitoring and recording all
adverse events and serious adverse events. All events will
be reported to local Health Authorities according to
Italian regulatory requirements and recorded in the
Novartis safety database.
Statistical considerations
The primary variable in the cross-sectional phase the
proportion of patients with a perennial form of aeroal-
lergens will be calculated as the ratio of the number of
patients with a perennial form of aeroallergens to the
total number of evaluable patients with a diagnosis of
severe allergic asthma at baseline.
The primary variable in the longitudinal phase, the
proportion of controlled patients based on ACQ both at
6 months and at 12 months, will be calculated as the ra-
tio between the patients who are controlled and the total
number of evaluable patients treated with omalizumab.
Both of the primary variables will be presented with 95%
confidence limit. The proportion of patients who change
status from controlled to un-controlled and vice-versa
between 6 and 12 months will also be presented.
With respect to the longitudinal phase, descriptive
statistics for each time point as well as changes versus
baseline will be provided for the ACQ total score, briefIPQ and EQ-5D-3 L. The patient compliance with oma-
lizumab use will be evaluated, as the ratio between the
numbers of administered injections during the observa-
tional period over the total number of planned injec-
tions, at 6 and 12 months after treatment start.
Sample size estimations
The sample size was determined on the basis of feasibility
criteria. According to the volume of patients managed by
the centers involved in this study, it is reasonable to sup-
pose the inclusion of 600 eligible outpatients are adequate
to arrive at sufficient sample size for the study. Consider-
ing that 5% patients may not be available for analysis, be-
cause of missing data or inclusion–exclusion criteria
violations, a total of 570 evaluable patients, allows a preci-
sion of estimate between 2.5% and 3.9% of the proportion
of patients with a perennial form of aeroallergens. In
particular the two sided 95% confidence interval will be
7.5%–12.5% for the 10% expected proportion of patients
and 31.1%-38.9% for the 35% expected proportion, based
on the results of ENFUMOSA study [3]. The proportion
of patients starting omalizumab at baseline is expected to
range between 30%–40%. Therefore, the sample size of
patients to be included in the longitudinal phase should
range from 180–240 patients. Assuming a 12 months
drop-out rate (including non-evaluable patients) of about
15%, 153–204 patients will be evaluable for the primary
endpoint in the longitudinal phase. Moreover, based on
the response of the omalizumab treatment as assessed by
using global evaluation of treatment effectiveness (GETE)
tool, it was appropriate to assume that the proportion
of patients with disease control after 12 months will
range from 50%–70%. A sample of 153 and 204 evalu-
able patients allows a precision of estimate between
7.9%–7.3% and 6.9%–6.3%, for the proportion of patients
who achieve the disease control at month 6 and maintains
it at month 12 [21,22].
The PROXIMA ancillary-study: exploratory proteomic
analysis on asthma biomarker
Rationale
Asthma is a complex respiratory disorder known to have
multiple causes, phenotypes, and treatment responses.
However, this complexity provides an opportunity for
personalized and targeted therapy by characterizing
specific biomarkers aiding to early diagnosis, assessing
therapeutic responses and even validation for new drug
targets [23]. Recent advances in mass spectrometry-
based proteomic approaches may facilitate identification
and characterization of new biomarkers in asthma and
subsequently improve understanding of their clinical
significance [24,25].
Currently, biomarkers that have known diagnostic and
clinical role in asthma are poorly characterized and there
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biomarkers during and after the treatment of severe
asthma.
Objectives
This ancillary study was designed to explore protein bio-
markers in patients with severe allergic asthma treated
with omalizumab and characterize potential biomarkers
in relation to the achievement and maintenance of
disease control. In addition, the study aims to identify
proteotypical peptides useful for the development of
diagnostic methods.
Study design and patient population
The PROXIMA ancillary study is planned to be con-
ducted at 8 centers in Italy with the aim of characteriz-
ing biomarkers related to severe allergic asthma by a
proteomic approach. The patients who would participate
in the longitudinal phase of PROXIMA study and pro-
vide additional informed consent specific to the ancillary
study will be enrolled.
Sample collections and investigations
Three samples for blood and urine will be collected from
eligible patients at baseline, 6 and 12 months of the
PROXIMA main study. The samples will be collected,
stored and shipped, as per instructions defined by the
central laboratory, to conduct the proteomic analysis at
Internal Medicine Department at Respiratory Diseases
Clinic, Hospital San Martino, University of Genoa.
A gel-free system and mass spectrometry will be used
to explore the proteins biomarkers. Protein species in com-
plex mixtures will be identified using innovative MudPIT
(Multidimensional Protein Identification Technology)
method [26]. The MudPIT method consists of a two-
dimensional chromatography coupled to the mass
spectrometry in tandem (2 DC-MS/MS) that allows the
identification of thousands of proteins simultaneously
from single complex sample [27].
Statistical analysis
There was no formal statistical hypothesis was set for
the study. Descriptive analyses will be performed. The
list and frequency of all proteins identified in the total
sample of patients will be provided at baseline, 6 and
12 months of omalizumab treatment. In order to assess
whether asthma protein biomarkers are related to the
achievement and maintenance of disease control, the
frequency of all identified proteins will be stratified by
responders and non-responders (as defined in the
PROXIMA main study). Since a large number of pos-
sible proteins are expected to be observed, Bonferroni’s
correction will be applied. The 95% confidence interval
will be calculated for both objectives.Discussion and conclusions
The PROXIMA observational study is designed to pro-
vide estimates on the number of patients with asthma
who are allergic to perennial allergens and to assess the
effectiveness of omalizumab in patients with severe
allergic asthma in the Italian population for the first
time. In various clinical studies, omalizumab has been
shown to improve asthma control and reduce exacerba-
tions in patients with inadequately-controlled severe
allergic asthma [4]. Current study is planned to be con-
ducted in a real-world setting in Italy and the result will
further confirm the control of asthma achieved and
maintained by omalizumab therapy in this population.
The exploratory proteomic analysis on asthma bio-
markers could identify proteins of interest in patients
with asthma, and link them to the patients’ level of
response to the disease and treatment. The new data
that will help to identify and characterize the best
responders to omalizumab treatment will be a step
towards personalized medicine.
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